Similar drugsTo uncover
Dosage form: & nbsp
Liofilizate for the preparation of solution for intracavitary administration and external application.

Composition:The active substance is a modified terrylitin enzyme, the product of covalent attachment of the proteolytic enzyme terrylitin to oxidized polyglucin.
Description:
The porous mass or powder is white or white with a yellowish tint of color.

Pharmacotherapeutic group:Proteolytic agent.
ATX: & nbsp
  • Proteolytic enzymes
  • Pharmacodynamics:
    TERRIDECASE ® is a proteolytic enzyme obtained by the covalent attachment of terrylitin to oxidized polyglucin.

    Terrylitin is a microbial proteolytic enzyme derived from native solutions of the Aspergillus terricola culture strain H-20, which has a broad spectrum of specific hydrolytic activity against various protein substrates, used as a necrolytic and wound healing agent for external use.

    The addition of polyglukine to terrylitin significantly reduced the allergic and locally irritating effect of the drug.

    The main mechanism of action is due to the proteolytic activity of terrylitin and its ability to hydrolyze various protein substrates, including mucins, and also to exert fibrinolytic action.
    Pharmacokinetics:Pharmacokinetics for this drug has not been studied.
    Indications:Purulent wounds, bedsores, trophic ulcers, abscesses of subcutaneous tissue of various locations (after opening, removal of nonviable tissues, thorough drainage of the abscess cavity), empyema of the pleura, coagulated hemothorax, purulent tracheobronchitis, bronchiectatic disease, sputum stasis after resection of the lungs.
    Contraindications:
    Individual intolerance, bleeding wounds, bleeding ulcers, ulcerated surfaces of malignant tumors, simultaneous reception of thrombolytic drugs in order to avoid hemorrhagic complications, not to enter the foci of inflammation (before autopsy). Contraindicated in pregnancy and during breastfeeding.

    Due to the lack of data on the use of the drug in children under 18 years of age (efficacy and safety of the drug is not established), do not prescribe the drug without consulting a doctor.
    Dosing and Administration:
    TERRIDECASE® is used in the form of a solution, for which the contents of 100U PE (Proteolytic Units) vial (ampules) are dissolved in 2-5 ml of distilled water or 0.9% solution of sodium chloride, or 0.25% solution of procaine.Apply externally, intrapleural, vupretraheapno, intrabronchial. On purulent wounds, bedsores, trophic ulcers impose napkins moistened with a solution of TERRIDECASE®, a waterproof bandage is applied from above; the dressing is changed once a day or every other day.

    With open sanation of the empyema of the pleura in the pleural cavity, injections of turuns with the drug are introduced.

    With closed puncture sanation, a solution of TERRIDECASE® at a dose of 100 PU is administered intrapleural both in the preoperative and postoperative periods 1 time per day. The course of treatment is 2-7 procedures.

    When the puncture treatment of postoperative hematorax is closed, the TERRIDECASE® solution is administered intrapleural at a dose of 100-200 PE per day with courses from 3-7 injections with aspiration of liquefied exudate (2-3 hours after the enzyme administration).

    With purulent tracheobronch, 3-5 ml of TERRIDECASE® (100 PU) solution is injected through the intubation tube (or intra-tracheal) 5-6 times a day for 3-4 days.

    At a delay of a sputum in the postoperative period after a resection of lungs intrabronchially 2-3 ml of a solution of TERRIDECASE ® (10-15 PE) are injected, For this purpose 100 PE of a drug are dissolved in 20 ml of 0.9% sodium chloride solution.The course of treatment is 1-3 procedures.
    Side effects:The rise in body temperature is due to the absorption of products of proteolysis of viable tissues with insufficient drainage of the wound, allergic reactions.
    Overdose:Cases of an overdose have not been revealed.
    Interaction:
    TERRIDECASE ® promotes better penetration into the focus of inflammation of other drugs (hydroxymethylquinoxaline dioxide, ampicillin + oxacillin, lincomycin). The drug is compatible with antimicrobial and chemotherapeutic agents.
    Special instructions:
    Do not use intravenously.

    In case of complications, it is necessary to create conditions for a good outflow of pus from the wound, or to cancel the drug.
    Effect on the ability to drive transp. cf. and fur:On the adverse impact on the ability to drive vehicles and management mechanisms have not been reported.
    Form release / dosage:
    Lyophilizate for the preparation of a solution for intracavitary administration and external application in ampoules (bottles) of 100 PU.

    Packaging:
    For 10 ampoules (bottles) in a box or pack of cardboard box with instructions for use of the drug, a knife for opening ampoules or a scarifier ampoule.
    Storage conditions:
    At temperatures from 0 to 10 ° C in a dry, dark place.

    Keep out of the reach of children.
    Shelf life:3 years. Do not use after the expiration date.
    Terms of leave from pharmacies:On prescription
    Registration number:LP-001258
    Date of registration:22.11.2011
    The owner of the registration certificate:SPbNIIVS FMBA, FSUE SPbNIIVS FMBA, FSUE Russia
    Manufacturer: & nbsp
    Information update date: & nbsp16.03.2016
    Illustrated instructions
      Instructions
      Up